Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

2024 GLP-1 RA products | Current Treatment: Physician Insights | US

Login to access report north_east
Contact sales account_box

Glucagon-like peptide-1 (GLP-1) receptor agonists, like SC semaglutide and liraglutide, and the glucose-dependent insulinotropic polypeptide (GIP) / GLP-1 receptor agonist tirzepatide have gained popularity in recent years owing to their impressive weight loss benefits. Additionally, these therapies are associated with robust glucose-level reductions and offer once-weekly and oral formulations. Because of these benefits, the GLP-1 and GIP / GLP-1 receptor agonists present an opportunity to address the intertwined challenges of treating type 2 diabetes (T2D) and obesity / overweight conditions. This content delves deep into the drivers of the GLP-1 and GIP / GLP-1 receptor agonist market, examining their usage and physicians’ perspectives.

Questions answered

  • What is the perception of endocrinologists versus primary care physicians regarding the use of GLP-1 and GIP / GLP-1 receptor agonists for the treatment of T2D and obesity / overweight conditions?
  • How have treatment practices evolved with the emergence of the GLP-1 and GIP / GLP-1 receptor agonists?
  • What factors influence the prescription choices of endocrinologists when prescribing a GLP-1 and GIP / GLP-1 receptor agonist to their T2D patients who are also obese / overweight?
  • When prescribing semaglutide to patients with T2D who are also obese / overweight, which brand (Ozempic, Rybelsus, or Wegovy) is most commonly prescribed by specialists, and what are the reasons?

Content highlights

  • Geography: United States
  • Primary research: survey of 101 U.S. endocrinologists and primary care physicians / general practitioners
  • Key drugs covered: Byetta, Ozempic, Saxenda, Trulicity, Wegovy, Zepbound
  • Key insights provided:
    • Factors influencing disease management and treatment decisions
    • Drivers and constraints of drug selection
    • Physician-reported treatment practices and brand-specific patient shares
    • Physician insight on persistency and compliance
    • Physician-reported recent / anticipated changes in brand usage or treatment approach

Product description

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Human Immunodeficiency Virus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Human Immunodeficiency Virus (US)
The HIV therapy market is crowded with several approved ARVs. Market growth is driven by the increasing acceptance of new, high-priced ARVs, particularly the latest STRs, which offer improved…
north_east
Report
Squamous Cell Carcinoma of the Head and Neck – Geographic Focus: China – China In-Depth – Squamous Cell Carcinoma of the Head and Neck
China’s SCCHN market is undergoing rapid transformation, driven by the expanding use of systemic therapies beyond traditional surgery and radiotherapy. Current treatment options include…
north_east
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…
north_east
Report
Bladder Cancer and Upper Tract Urothelial Carcinoma – Geographic Focus: China – Bladder Cancer and Upper Tract Urothelial Carcinoma – China In-Depth – China
China’s bladder cancer market is entering a period of accelerated expansion, as novel branded therapies reshape systemic management. A major growth driver is the expanding role of immune…
north_east
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a widely drug-treated condition managed with multiple drug classes, most commonly selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east